ArticleMolecular cancer2014

YC-1 enhances the anti-tumor activity of sorafenib through inhibition of signal transducer and activator of transcription 3 (STAT3) in hepatocellular carcinoma.

Jian Kong et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.